Head and Neck Cancer clinical trials at UCSF
38 in progress, 14 open to eligible people
Head and neck cancer affects the mouth, throat, and nearby areas. UCSF is testing new cancer drugs like AB248 and NX-1607, as well as exploring treatment combinations that include radiation. UCSF is also looking at ways to manage side effects like taste changes and jaw stiffness from cancer therapy.
AB248 Alone or in Combination with Pembrolizumab in Adult Patients with Solid Tumors
open to eligible people ages 18 years and up
This is a phase I, First-in-Human (FIH), open-label study to evaluate the safety, tolerability, pharmacokinetic (PK) profile, and preliminary efficacy of AB248 as monotherapy OR in combination with pembrolizumab in adult participants with locally…
San Francisco, California and other locations
NX-1607 in Adults With Advanced Malignancies
open to eligible people ages 18 years and up
This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies.
San Francisco, California and other locations
Taste Dysfunction With Miraculin in Head and Neck Cancer Patients Receiving Radiation Therapy
open to eligible people ages 18 years and up
Patients diagnosed with head and neck cancer who receive radiation therapy with and without chemotherapy develop altered sense of taste due to treatment effect, which typically arises in the second week of radiation therapy and progresses throughout …
San Francisco, California
Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer
open to eligible people ages 18 years and up
This phase II/III trial compares whether cisplatin given weekly with radiation therapy is better tolerated than cisplatin given every three weeks with radiation therapy for the treatment of head and neck cancer that has spread to other places in the …
San Francisco, California and other locations
Low-Cost Therapeutic Device in Managing Head and Neck Cancer Patients With Radiation-Related Trismus
open to eligible people ages 18 years and up
This trial evaluates how well a new therapeutic device works in managing trismus in patients who received radiation treatment for head and neck cancer. Radiation therapy is a common form of treatment in patients with head and neck cancers. However,…
San Francisco, California
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
open to eligible people ages 60 years and up
This is a global, open-label, randomized, 2-arm, Investigator's choice Phase 3 (Pivotal Stage) study to investigate the efficacy and safety of JNJ-90301900 (NBTXR3) / radiation therapy (RT)±cetuximab versus RT±cetuximab in treatment-naïve,…
San Francisco, California and other locations
NBTXR3 Activated by Radiotherapy for Patients with Advanced Cancers Treated with an Anti-PD-1 Therapy
open to eligible people ages 18 years and up
The 1100 study is an open-label, Phase I, dose escalation and expansion prospective clinical study to assess the safety of intratumoral injection of NBTXR3 activated by radiotherapy in combination with anti-PD-1 therapy.
San Francisco, California and other locations
Nisin in Oral Cavity Squamous Cell Carcinoma (OCSCC)
open to eligible people ages 18 years and up
This is a study of oral nisin administration in patients with OSCC who are undergoing complete surgical resection surgery with or without adjuvant radiation/chemoradiation as part of their routine care at the University of California, San Francisco…
San Francisco, California
Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck
open to eligible people ages 18 years and up
To determine the effect of neoadjuvant atezolizumab alone or in combination with other immune modulating agents on T-cell infiltration in advanced SCCHN. To determine the impact of neo-adjuvant immunotherapy on surgical outcomes.
San Francisco, California
Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies
open to eligible people ages 18 years and up
The purpose of this clinical trial is to provide study medicine(s) and learn about their safety. This study is seeking participants who: - Have benefited from ongoing study treatment as determined by the study doctor in a Pfizer-sponsored…
San Francisco, California and other locations
Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
open to eligible people ages 18 years and up
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity when ABBV-400 is given to adult participants to treat advanced solid …
San Francisco, California and other locations
Fatigue and Molecular Mechanisms in Cancer Patients Receiving CCRT
open to eligible people ages 18 years and up
Cancer-related fatigue (CRF) is a significant problem for cancer patients. This prospective, basic science, observational study will evaluate for changes in CRF associated with molecular characteristics prior to, during, and at the completion of…
San Francisco, California
People Living With HIV, Oral and Oropharyngeal Cancer, and Health Equity
open to eligible people ages 18 years and up
This is an exploratory qualitative study among People Living With HIV (PLWH) of diverse racial/ethnic and sexual and gender minority (SGM) identities to explore individual, interpersonal, and structural oral health equity factors that serve as…
San Francisco, California
Tumor-Informed ctDNA Testing of Head & Neck Intent Treatment of Squamous Cell Carcinoma
open to eligible people ages 18 years and up
This is a single-center, non-interventional, observational study that evaluates the correlation of circulating tumor DNA (ctDNA) testing to cancer relapse for participants with head and neck squamous cell carcinomas (HNC) after curative-intent…
San Francisco, California
Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
Sorry, currently not accepting new patients, but might later
This phase II/III trial studies how well sentinel lymph node biopsy works and compares sentinel lymph node biopsy surgery to standard neck dissection as part of the treatment for early-stage oral cavity cancer. Sentinel lymph node biopsy surgery is…
San Francisco, California and other locations
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
Sorry, not currently recruiting here
This phase II/III trial studies how well radiation therapy works when given together with cisplatin, docetaxel, cetuximab, and/or atezolizumab after surgery in treating patients with high-risk stage III-IV head and neck cancer the begins in the…
San Francisco, California and other locations
Beta-only IL-2 ImmunoTherapY Study
Sorry, not currently recruiting here
This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in…
San Francisco, California and other locations
Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
Sorry, not currently recruiting here
The main purpose of this study is to assess the efficacy and safety of volrustomig compared to observation in participants with unresected locally advanced head and neck squamous cell carcinoma (LA-HNSCC) who have not progressed after receiving…
San Francisco, California and other locations
WU-NK-101 in Combination With Cetuximab
Sorry, in progress, not accepting new patients
This study is a Phase 1b open-label study designed to characterize the safety, tolerability, and preliminary anti-tumor activity of WU-NK-101 in combination with cetuximab in patients with advanced and/or metastatic CRC (Cohort 1), and in patients…
San Francisco, California and other locations
Cemiplimab and ISA101b in Patients With Recurrent/Metastatic HPV16 Positive OPC
Sorry, in progress, not accepting new patients
This will be an open-label, phase 2 study in which subjects will receive ISA101b and cemiplimab.
San Francisco, California and other locations
Cemiplimab ± ISA101b in HPV16-Positive OPC
Sorry, in progress, not accepting new patients
This will be a blinded, placebo-controlled, randomized, phase 2 study in which subjects will be randomly assigned 1:1 to cemiplimab plus placebo or cemiplimab plus ISA101b.
San Francisco, California and other locations
Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Sorry, in progress, not accepting new patients
This is a Phase 1a/1b, open-label, multicenter, global, dose-escalation study designed to evaluate the safety, tolerability, immune response, and pharmacokinetics of autogene cevumeran (RO7198457) as a single agent and in combination with…
San Francisco, California and other locations
TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer
Sorry, in progress, not accepting new patients
The main aim of this study is to check for side effects and tolerability of TAK-186 (also known as MVC-101) in adults with unremovable advanced or metastatic cancer. Another aim is to characterize and evaluate the activity of TAK-186 (MVC-101).…
San Francisco, California and other locations
TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors
Sorry, in progress, not accepting new patients
TransCon TLR7/8 Agonist is an investigational drug being developed for treatment of locally advanced or metastatic solid tumors. This Phase 1/2 study will evaluate TransCon TLR7/8 Agonist as monotherapy or in combination with pembrolizumab in dose…
San Francisco, California and other locations
Autologous Muscle Derived Cells for Treatment of Tongue Dysphagia
Sorry, in progress, not accepting new patients
The primary objective of this double-blind, randomized, placebo-controlled, multicenter clinical trial is to evaluate the safety of AMDC-GIR during the 24 months following 2 consecutive treatments of tongue dysphagia in male and female patients who…
San Francisco, California and other locations
Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Sorry, in progress, not accepting new patients
This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor an NTRK1/2/3, ROS1, or ALK gene fusion. Patients will be assigned to different baskets according to …
San Francisco, California and other locations
De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer
Sorry, in progress, not accepting new patients
This phase II/III trial studies how well a reduced dose of radiation therapy works with nivolumab compared to cisplatin in treating patients with human papillomavirus (HPV)-positive oropharyngeal cancer that is early in its growth and may not have…
San Francisco, California and other locations
Pembrolizumab in Relapsed, Locally Recurrent Squamous Cell Cancer of the Head and Neck
Sorry, in progress, not accepting new patients
The purpose of this study is to determine whether pembrolizumab, when given after salvage surgery, is effective in increasing the time a person with squamous cell cancer of the head and neck remains disease-free following locoregional disease…
San Francisco, California and other locations
P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects with Advanced or Metastatic Solid Tumors
Sorry, in progress, not accepting new patients
A Phase 1, open label, dose escalation and expanded cohort study of P-MUC1C-ALLO1 in adult subjects with advanced or metastatic epithelial derived solid tumors, including but not limited to the tumor types listed below.
San Francisco, California and other locations
Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer
Sorry, in progress, not accepting new patients
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from …
San Francisco, California and other locations
Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin
Sorry, in progress, not accepting new patients
This phase II/III trial studies how well radiation therapy works with durvalumab or cetuximab in treating patients with head and neck cancer that has spread to a local and/or regional area of the body who cannot take cisplatin. Radiation therapy…
San Francisco, California and other locations
Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery
Sorry, in progress, not accepting new patients
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is…
San Francisco, California and other locations
Reduced-Dose Intensity-Modulated Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Oropharyngeal Cancer
Sorry, in progress, not accepting new patients
This randomized phase II trial studies the side effects and how well modestly reduced-dose intensity-modulated radiation therapy (IMRT) with or without cisplatin works in treating patients with oropharyngeal cancer that has spread to other places in …
San Francisco, California and other locations
PDS0101 and Pembrolizumab Combination I/O in Subjects with HPV16 + Recurrent And/or Metastatic HNSCC
Sorry, in progress, not accepting new patients
VERSATILE-002 is a Phase 2, open-label, multicenter study of the efficacy and safety of PDS0101 administered in combination with pembrolizumab in adults with HPV16 and PD-L1 positive recurrent or metastatic head and neck squamous cell carcinoma…
San Francisco, California and other locations
Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
Sorry, in progress, not accepting new patients
The purpose of this study is to evaluate the safety and efficacy of the combination of retifanlimab plus INCAGN02385 and retifanlimab plus INCAGN02385 and INCAGN02390 compared with retifanlimab alone as first-line treatment in PD-L1-positive and…
San Francisco, California and other locations
MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck
Sorry, in progress, not accepting new patients
This multicentre, open-label, Phase 1b/2 study is designed as a 2 part study consisting of a dose-escalation, safety run-in Part A and a dose-expansion Part B
San Francisco, California and other locations
Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer
Sorry, in progress, not accepting new patients
This randomized phase II trial studies how well transoral surgery followed by low-dose or standard-dose radiation therapy works in treating patients with human papilloma virus (HPV) positive stage III-IVA oropharyngeal cancer. Radiation therapy uses …
San Francisco, California and other locations
Treatment of Radiation and Cisplatin Induced Toxicities with Tempol
Sorry, not currently recruiting here
A 10 week trial to assess the ability of Tempol to prevent and/or reduce toxicities associated with cisplatin and radiation treatment in head and neck cancer patients. Over the course of the 10 week trial, mucositis, nephrotoxicity, and ototoxicity…
San Francisco, California and other locations
Our lead scientists for Head and Neck Cancer research studies include Pamela Munster Jason Chan Andrea Park, MD Clark Rosen Hope Rugo Sue Yom, MD, PhD Alain Algazi.
Last updated: